{"commentary":{"count":63,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":32,"podcast":20,"x_thread":11},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05605899\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ZUMA-23","nct_id":"NCT05605899","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=zuma-23-nct05605899. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ZUMA-23","arms":[{"description":"Participants will receive cyclophosphamide 500 mg/m\\^2/day intravenously (IV) and fludarabine 30 mg/m\\^2/day IV lymphodepletion chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0.","label":"Axicabtagene Ciloleucel","type":"EXPERIMENTAL"},{"description":"Participants will receive the investigator's choice of one of the following therapies/dosing schedules:\n\n* Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for a total of 6 cycles (21-day cycle)\n\n  * Rituximab 375 mg/m\\^2 on Day 1\n  * Cyclophosphamide 750 mg/m\\^2 on Day 1\n  * Doxorubicin 50 mg/m\\^2 on Day 1\n  * Vincristine 1.4 mg/m\\^2 (maximum 2 mg) on Day 1\n  * Prednisone 40 mg/m\\^2 on Day 1 through Day 5\n* Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) for a total of 6 cycles (21-day cycle)\n\n  * Rituximab 375 mg/m\\^2 on Day 1\n  * Etoposide 50 mg/m\\^2 on Days 1 to 4\n  * Doxorubicin 10 mg/m\\^2 on Days 1 to 4\n  * Vincristine 0.4 mg/m\\^2 on Days 1 to 4\n  * Cyclophosphamide 750 mg/m\\^2 on Day 5\n  * Prednisone 60 mg/m\\^2 twice daily on Days 1 to 5","label":"Standard of Care Therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-03","type":"ESTIMATED"},"conditions":["High-risk Large B-cell Lymphoma (LBCL)"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Axicabtagene Ciloleucel","type":"BIOLOGICAL"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Fludarabine","type":"DRUG"},{"name":"Etoposide","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Doxorubicin","type":"DRUG"},{"name":"Vincristine","type":"DRUG"},{"name":"Prednisone","type":"DRUG"}],"last_update":"2026-04-15","lead_sponsor":"Kite, A Gilead Company","official_title":"An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free Survival (EFS) by Blinded Central Assessment","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2023-02-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT05605899"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/zuma-23-nct05605899"}